Recent Updates
Recently added Catalysts

IPH4102

Phase 2

Lymphoma, T-Cell | Monoclonal antibody | Oncology |Innate Pharma S.A.|Last Updated: Apr 29, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment170
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03902184IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell LymphomaPHASE2 COMPLETED 170 — — May 22, 2019Jan 8, 2026Apr 29, 202653 United States, Austria +6
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Objective Response Rate (ORR)
From the first dose until study completion, an expected average of 2 years

Using the Olsen (2011, JCO) criteria (All cohorts)

Secondary Endpoints
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (All cohorts)
From first dose until study completion, an expected average of 2 years
Quality of life (QoL) (All cohorts)
Through study completion, an expected average of 2 years
pruritus (All cohorts)
Through study completion, an expected average of 2 years
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cohort 1: Relapsed/refractory Sezary SyndromeEXPERIMENTALIPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressingEXPERIMENTALIPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing (closed)EXPERIMENTALIPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
Cohort All comers: Stage IB-IV Mycosis Fungoides,KIR3DL2 expressing and non-expressingEXPERIMENTALIPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
Interventions
NameTypeDescription
IPH4102BIOLOGICALPatients will receive a flat dose of 750mg
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites53

Inclusion criteria SS patients (Cohort 1): 1. Relapsed and/or refractory stage IVA, IVB SS who have received at least two prior systemic therapies; 2. Prior treatment with mogamulizumab; 3. Patients should have blood stage B2 at screening based on central evaluation by flow cytometry; 4. Feasibili...

Countries:United StatesAustriaBelgiumFranceGermanyItalyPolandSpain
Unlock Eligibility Criteria
Competitive Landscape -Cutaneous T-Cell Lymphoma 4 trials
CompanyTickerTrialsLead PhaseDrugs
Soligenix, Inc.SNGX1PHASE3Hypericin
Incyte CorporationINCY2PHASE2Ruxolitinib, Pembrolizumab
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK1 — Undisclosed
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
MEDIUMMay 30, 2026NCT03902184TRIAL_REMOVED: changed
MEDIUMMay 30, 2026NCT03902184TRIAL_REMOVED: changed
MEDIUMMay 30, 2026NCT03902184TRIAL_REMOVED: changed
MEDIUMMay 30, 2026NCT03902184TRIAL_REMOVED: changed
HIGHMay 26, 2026NCT03902184Status: ACTIVE_NOT_RECRUITING → COMPLETED
LOWMay 24, 2026NCT03902184studyFirstPostDate: changed